Industry Trend Analysis - Underdeveloped Frontier Markets Present Limited Drugmaker Opportunities - MAR 2017
BMI View : Opportunities for pharmaceutical companies in the Middle East and North Africa region will be diverse. Indeed, international firms will benefit greatly from identifying the bright spots in the region and avoiding those markets where the risks outweigh the opportunities. Despite the push towards expanding healthcare access throughout the region, longstanding economic and political fragilities will continue to create some tough operating environment s for foreign drugmakers. As such, multinational interest will, for the most part, be skewed towards the larger markets of the region.
The Middle East and North Africa (MENA) pharmaceutical market is highly diverse and as such, the challenges and opportunities posed to multinational pharmaceutical firms also differ greatly depending on geography. Broadly speaking, Saudi Arabia, Egypt and the UAE offer the greatest commercial incentives owing to their relative market size and level of development - both economically and in a pharmaceutical capacity. This is reflected by the fact that most international firms in MENA choose to centre their operations within these key markets. In contrast, many of the smaller pharmaceutical markets pose significant risks for multinational drugmakers and as such are often overlooked.
An Overview Of T he 10 Smallest Markets
|Small Markets Provide Few Opportunities|
|MENA: Pharmaceutical Market Size Per Country, USDbn (2016)|
|f = BMI forecast. Source: UN Comtrade, National s ources, BMI|